$13.66
1.23% yesterday
Nasdaq, Sep 23, 10:11 pm CET
ISIN
NL0010696654
Symbol
QURE

uniQure N.V. Stock price

$13.66
-1.89 12.15% 1M
-1.11 7.52% 6M
-4.00 22.65% YTD
+8.61 170.50% 1Y
-3.64 21.04% 3Y
-24.31 64.02% 5Y
-13.86 50.36% 10Y
-0.95 6.50% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
-0.17 1.23%
ISIN
NL0010696654
Symbol
QURE
Industry

Key metrics

Basic
Market capitalization
$758.8m
Enterprise Value
$888.9m
Net debt
$130.1m
Cash
$377.0m
Shares outstanding
54.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
52.9 | 41.5
EV/Sales
62.0 | 48.6
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-1.2%
Return on Equity
3,547.9%
ROCE
-30.6%
ROIC
-84.6%
Debt/Equity
-126.8
Financials (TTM | estimate)
Revenue
$14.3m | $18.3m
EBITDA
$-150.8m | $-151.1m
EBIT
$-166.3m | $-182.5m
Net Income
$-199.0m | $-189.9m
Free Cash Flow
$-174.2m
Growth (TTM | estimate)
Revenue
-48.3% | -32.6%
EBITDA
34.1% | 8.1%
EBIT
30.9% | -3.0%
Net Income
30.1% | 20.7%
Free Cash Flow
-57.5%
Margin (TTM | estimate)
Gross
82.6%
EBITDA
-1,051.8% | -826.4%
EBIT
-1,159.9%
Net
-1,388.0% | -1,038.6%
Free Cash Flow
-1,215.3%
More
EPS
$-3.6
FCF per Share
$-3.2
Short interest
16.7%
Employees
209
Rev per Employee
$130.0k
Show more

Is uniQure N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

uniQure N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a uniQure N.V. forecast:

18x Buy
90%
2x Hold
10%

Analyst Opinions

20 Analysts have issued a uniQure N.V. forecast:

Buy
90%
Hold
10%

Financial data from uniQure N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
14 14
48% 48%
100%
- Direct Costs 2.49 2.49
91% 91%
17%
12 12
903% 903%
83%
- Selling and Administrative Expenses 46 46
29% 29%
324%
- Research and Development Expense 135 135
22% 22%
940%
-151 -151
34% 34%
-1,052%
- Depreciation and Amortization 16 16
28% 28%
108%
EBIT (Operating Income) EBIT -166 -166
31% 31%
-1,160%
Net Profit -199 -199
30% 30%
-1,388%

In millions USD.

Don't miss a Thing! We will send you all news about uniQure N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

uniQure N.V. Stock News

Neutral
Seeking Alpha
18 days ago
uniQure's lead candidate AMT-130 targets Huntington's disease with promising clinical data and potential for accelerated FDA approval, driving my continued Buy rating. The company has strong cash reserves, alignment with the FDA on trial design and CMC, and a critical three-year data readout due soon as a major catalyst. Despite volatility and regulatory headwinds, AMT-130's efficacy and safety...
Neutral
GlobeNewsWire
19 days ago
~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~
Neutral
Seeking Alpha
about 2 months ago
uniQure N.V. (NASDAQ:QURE ) Q2 2025 Earnings Call July 29, 2025 8:30 AM ET Company Participants Chiara Russo - Senior Director of Investor Relations Matthew Kapusta - CEO & Executive Director Walid Abi-Saab - Chief Medical Officer Christian Klemt - CFO, Principal Financial Officer & GM of Amsterdam Site Conference Call Participants Debjit Chattopadhyay - Guggenheim Securities, LLC, Research Div...
More uniQure N.V. News

Company Profile

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Head office Netherlands
CEO Matt Kapusta
Employees 209
Founded 2012
Website www.uniqure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today